Free Trial
NASDAQ:CYCC

Cyclacel Pharmaceuticals (CYCC) Stock Price, News & Analysis

Cyclacel Pharmaceuticals logo
$0.23 -0.01 (-6.01%)
Closing price 07/3/2025 03:58 PM Eastern
Extended Trading
$0.23 0.00 (0.00%)
As of 07/3/2025 04:41 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Cyclacel Pharmaceuticals Stock (NASDAQ:CYCC)

Key Stats

Today's Range
$0.22
$0.25
50-Day Range
$0.23
$5.66
52-Week Range
$0.22
$39.84
Volume
2.59 million shs
Average Volume
453,490 shs
Market Capitalization
$5.54 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
Hold

Company Overview

Cyclacel Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
10th Percentile Overall Score

CYCC MarketRank™: 

Cyclacel Pharmaceuticals scored higher than 10% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Cyclacel Pharmaceuticals is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Cyclacel Pharmaceuticals is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Read more about Cyclacel Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    2.67% of the float of Cyclacel Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Cyclacel Pharmaceuticals has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Cyclacel Pharmaceuticals has recently increased by 1,759.69%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Cyclacel Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Cyclacel Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    2.67% of the float of Cyclacel Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Cyclacel Pharmaceuticals has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Cyclacel Pharmaceuticals has recently increased by 1,759.69%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Cyclacel Pharmaceuticals has a news sentiment score of -0.11. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.54 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 11 news articles for Cyclacel Pharmaceuticals this week, compared to 1 article on an average week.
  • Search Interest

    5 people have searched for CYCC on MarketBeat in the last 30 days. This is an increase of 25% compared to the previous 30 days.
  • MarketBeat Follows

    Only 1 people have added Cyclacel Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Cyclacel Pharmaceuticals insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    96.90% of the stock of Cyclacel Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 23.58% of the stock of Cyclacel Pharmaceuticals is held by institutions.

  • Read more about Cyclacel Pharmaceuticals' insider trading history.
Receive CYCC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cyclacel Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

CYCC Stock News Headlines

Everyone’s watching Nvidia right now. Here’s why I’m excited.
So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal with Saudi Arabia to power its new AI empire 🤯 We’re talking about hundreds of thousands of chips, including their latest Grace Blackwell supercomputer.
Cyclacel Pharmaceuticals Announces Stock Split
Cyclacel (CYCC) Share News Today - Investing.com UK
See More Headlines

CYCC Stock Analysis - Frequently Asked Questions

Cyclacel Pharmaceuticals' stock was trading at $90.24 on January 1st, 2025. Since then, CYCC shares have decreased by 99.7% and is now trading at $0.2330.

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) issued its earnings results on Wednesday, April, 2nd. The biotechnology company reported ($79.20) earnings per share for the quarter, missing analysts' consensus estimates of ($69.60) by $9.60. The biotechnology company earned $0.01 million during the quarter, compared to analysts' expectations of $0.01 million.

Cyclacel Pharmaceuticals shares reverse split on the morning of Monday, July 7th 2025.The 1-15 reverse split was announced on Wednesday, July 2nd 2025. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, July 3rd 2025. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

Shares of CYCC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Cyclacel Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), GE Aerospace (GE), Broadcom (AVGO), Advanced Micro Devices (AMD), CymaBay Therapeutics (CBAY) and Arista Networks (ANET).

Company Calendar

Last Earnings
4/02/2025
Record date for 5/1 Dividend
4/29/2025
Ex-Dividend for 5/1 Dividend
4/29/2025
Dividend Payable
5/01/2025
Today
7/04/2025
Next Earnings (Estimated)
8/13/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:CYCC
Employees
14
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$11.21 million
Pretax Margin
-55,535.71%

Debt

Sales & Book Value

Annual Sales
$40 thousand
Price / Cash Flow
N/A
Book Value
($3.93) per share
Price / Book
-0.06

Miscellaneous

Free Float
737,000
Market Cap
$5.54 million
Optionable
Optionable
Beta
0.03

Social Links

Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

This page (NASDAQ:CYCC) was last updated on 7/4/2025 by MarketBeat.com Staff
From Our Partners